Effect of 1-Substitution on Tetrahydroisoquinolines as Selective Antagonists for the Orexin-1 Receptor

ACS Chemical Neuroscience

Volumn 6, Issue 4, 2015, Pages 599-614

  Perrey, David A ^a   German, Nadezhda A ^a   Decker, Ann M ^a   Thorn, David ^b   Li, Jun Xu ^b   Gilmour, Brian P ^a   Thomas, Brian F ^a   Harris, Danni L ^a   Runyon, Scott P ^a   Zhang, Yanan ^a  

^a RTI INTERNATIONAL   (United States)

^b UNIVERSITY AT BUFFALO   (United States)

Author keywords

antagonist; Orexin; selective; tetrahydroisoquinoline

Indexed keywords

2 [1 [(3 AMINO 4 HYDROXYPHENYL)METHYL] 6,7 DIMETHOXY 1,2,3,4 TETRAHYDROISOQUINOLIN 2 YL] N BENZYLACETAMIDE; 2 [1 [(3 AMINO 4 METHOXYPHENYL)METHYL] 6,7 DIMETHOXY 1,2,3,4 TETRAHYDROISOQUINOLIN 2 YL] N BENZYLACETAMIDE; 4 [(6,7 DIMETHOXY 1,2,3,4 TETRAHYDROISOQUINOLIN 1 YL)METHYL] 2 METHOXYPHENOL; 4 [[2 [(BENZYLCARBAMOYL)METHYL] 6,7 DIMETHOXY 1,2,3,4 TETRAHYDROISOQUINOLIN 1 YL]METHYL] 2 METHOXYPHENYL 4 METHYLBENZENE 1 SULFONATE; 4 [[2 [(BENZYLCARBAMOYL)METHYL] 6,7 DIMETHOXY 1,2,3,4 TETRAHYDROISOQUINOLIN 1 YL]METHYL] 2 METHOXYPHENYL BENZENESULFONATE; 4 [[2 [(BENZYLCARBAMOYL)METHYL] 6,7 DIMETHOXY 1,2,3,4 TETRAHYDROISOQUINOLIN 1 YL]METHYL] 2 METHOXYPHENYL BUTANOATE; 4 [[2 [(BENZYLCARBAMOYL)METHYL] 6,7 DIMETHOXY 1,2,3,4 TETRAHYDROISOQUINOLIN 1 YL]METHYL] 2 METHOXYPHENYL METHANESULFATE; N BENZYL 2 [1 [(3 ACETAMIDO 4 METHOXYPHENYL)METHYL] 6,7 DIMETHOXY 1,2,3,4 TETRAHYDROISOQUINOLIN 2 YL]ACETAMIDE; N BENZYL 2 [1 [(4 BUTOXY 3 METHOXYPHENYL)METHYL] 6,7 DIMETHOXY 1,2,3,4 TETRAHYDROISOQUINOLIN 2 YL]ACETAMIDE; N BENZYL 2 [1 [(4 HYDROXY 3 METHOXYPHENYL)METHYL] 6,7 DIMETHOXY 1,2,3,4 TETRAHYDROISOQUINOLIN 2 YL]ACETAMIDE; N BENZYL 2 [1 [(4 HYDROXY 3 NITROPHENYL)METHYL] 6,7 DIMETHOXY 1,2,3,4 TETRAHYDROISOQUINOLIN 2 YL]ACETAMIDE; N BENZYL 2 [1 [[3 (BENZYLAMINO) 4 METHOXYPHENYL]METHYL] 6,7 DIMETHOXY 1,2,3,4 TETRAHYDROISOQUINOLIN 2 YL]ACETAMIDE; N BENZYL 2 [1 [[3 (DIETHYLAMINO) 4 METHOXYPHENYL]METHYL] 6,7DIMETHOXY 1,2,3,4 TETRAHYDROISOQUINOLIN 2 YL]ACETAMIDE; N BENZYL 2 [1 [[3 (DIMETHYLAMINO) 4 METHOXYPHENYL]METHYL] 6,7 DIMETHOXY 1,2,3,4 TETRAHYDROISOQUINOLIN 2 YL]ACETAMIDE; N BENZYL 2 [1 [[3 (DIPROPYLAMINO) 4 METHOXYPHENYL]METHYL] 6,7 DIMETHOXY 1,2,3,4 TETRAHYDROISOQUINOLIN 2 YL]ACETAMIDE; N BENZYL 2 [1 [[3 (ETHYLAMINO) 4 METHOXYPHENYL]METHYL] 6,7 DIMETHOXY 1,2,3,4 TETRAHYDROISOQUINOLIN 2 YL]ACETAMIDE; N BENZYL 2 [1 [[4 (BENZYLOXY) 3 METHOXYPHENYL]METHYL] 6,7 DIMETHOXY 1,2,3,4 TETRAHYDROISOQUINOLIN 2 YL]ACETAMIDE; N BENZYL 2 [6 METHOXY 1[(3 METHOXY 4 PROPOXYPHENYL)METHYL] 7 PROPOXY 1,2,3,4 TETRAHYDROISOQUINOLIN 2 YL]ACETAMIDE; N BENZYL 2 [6,7 DIMETHOXY 1 [(4 METHOXY 3 NITROPHENYL)METHYL] 1,2,3,4 TETRAHYDROISOQUINOLIN 2 YL]ACETAMIDE; N BENZYL 2 [6,7 DIMETHOXY 1 [[3 METHOXY 4 (4 PHENOXYBUTOXY)PHENYL]METHYL] 1,2,3,4 TETRAHYDROISOQUINOLIN 2 YL]ACETAMIDE; N BENZYL 2 [6,7 DIMETHOXY 1 [[3 METHOXY 4 (PYRIDIN 2 YLMETHOXY)PHENYL]METHYL] 1,2,3,4 TETRAHYDROISOQUINOLIN 2 YL]ACETAMIDE; N BENZYL 2 [6,7 DIMETHOXY 1 [[3 METHOXY 4 (PYRIDIN 3 YLMETHOXY)PHENYL]METHYL] 1,2,3,4 TETRAHYDROISOQUINOLIN 2 YL]ACETAMIDE; N BENZYL 2 [6,7 DIMETHOXY 1 [[3 METHOXY 4 [2 (PIPERIDIN 1 YL)ETHOXY]PHENYL]METHYL] 1,2,3,4 TETRAHYDROISOQUINOLIN 2 YL]ACETAMIDE; N BENZYL 2 [6,7 DIMETHOXY 1 [[4 METHOXY 3 (PROPYLAMINO)PHENYL]METHYL] 1,2,3,4 TETRAHYDROISOQUINOLIN 2 YL]ACETAMIDE; N [2 (3,4 DIMETHOXYPHENYL)ETHYL] 2 (3 HYDROXY 4 METHOXYPHENYL)ACETAMIDE; N [5 [[2 [BENZYLCARBAMOYL)METHYL] 6,7 DIMETHOXY 1,2,3,4 TETRAHYDROISOQUINOLIN 1 YL]METHYL 2 METHOXYPHENYLBUTANAMIDE; OREXIN 1 RECEPTOR; RECEPTOR BLOCKING AGENT; TETRAHYDROISOQUINOLINE DERIVATIVE; UNCLASSIFIED DRUG; UNINDEXED DRUG; CALCIUM; COCAINE; DOPAMINE UPTAKE INHIBITOR; OREXIN RECEPTOR; OREXIN RECEPTOR ANTAGONIST;

ADULT; ANIMAL EXPERIMENT; ARTICLE; CONTROLLED STUDY; DISSOCIATION CONSTANT; DRUG DESIGN; DRUG POTENCY; DRUG SCREENING; DRUG SELECTIVITY; DRUG SYNTHESIS; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MALE; NONHUMAN; PRIORITY JOURNAL; RAT; STRUCTURE ACTIVITY RELATION; ANIMAL; CHEMICAL STRUCTURE; CHEMISTRY; CHO CELL LINE; CRICETULUS; DOSE RESPONSE; DRUG EFFECTS; GENETICS; LOCOMOTION; METABOLISM; PHYSIOLOGY; SPRAGUE DAWLEY RAT; SYNTHESIS;

RATTUS;

ANIMALS; CALCIUM; CHO CELLS; COCAINE; CRICETULUS; DOPAMINE UPTAKE INHIBITORS; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; LOCOMOTION; MALE; MOLECULAR STRUCTURE; OREXIN RECEPTOR ANTAGONISTS; OREXIN RECEPTORS; RATS, SPRAGUE-DAWLEY; TETRAHYDROISOQUINOLINES;

EID: 84927922914     PISSN: None     EISSN: 19487193     Source Type: Journal    
DOI: 10.1021/cn500330v     Document Type: Article

References (42)

1. Sakurai, T., Amemiya, A., Ishii, M., Matsuzaki, I., Chemelli, R. M., Tanaka, H., Williams, S. C., Richardson, J. A., Kozlowski, G. P., Wilson, S., Arch, J. R., Buckingham, R. E., Haynes, A. C., Carr, S. A., Annan, R. S., McNulty, D. E., Liu, W. S., Terrett, J. A., Elshourbagy, N. A., Bergsma, D. J., and Yanagisawa, M. (1998) Orexins and orexin receptors: A family of hypothalamic neuropeptides and G protein-coupled receptors that regulate feeding behavior Cell 92, 573 - 585
2. de Lecea, L., Kilduff, T. S., Peyron, C., Gao, X., Foye, P. E., Danielson, P. E., Fukuhara, C., Battenberg, E. L., Gautvik, V. T., Bartlett, F. S., 2nd, Frankel, W. N., van den Pol, A. N., Bloom, F. E., Gautvik, K. M., and Sutcliffe, J. G. (1998) The hypocretins: hypothalamus-specific peptides with neuroexcitatory activity Proc. Natl. Acad. Sci. U. S. A. 95, 322 - 327
3. Peyron, C., Tighe, D. K., van den Pol, A. N., de Lecea, L., Heller, H. C., Sutcliffe, J. G., and Kilduff, T. S. (1998) Neurons containing hypocretin (orexin) project to multiple neuronal systems J. Neurosci. 18, 9996 - 10015
4. Nambu, T., Sakurai, T., Mizukami, K., Hosoya, Y., Yanagisawa, M., and Goto, K. (1999) Distribution of orexin neurons in the adult rat brain Brain Res. 827, 243 - 260
5. Li, J., Hu, Z., and de Lecea, L. (2014) The hypocretins/orexins: Integrators of multiple physiological functions Br. J. Pharmacol. 171, 332 - 350
6. Kukkonen, J. P. and Leonard, C. S. (2014) Orexin/hypocretin receptor signalling cascades Br. J. Pharmacol. 171, 314 - 331
7. Leonard, C. S. and Kukkonen, J. P. (2014) Orexin/hypocretin receptor signalling: A functional perspective Br. J. Pharmacol. 171, 294 - 313
8. Marcus, J. N., Aschkenasi, C. J., Lee, C. E., Chemelli, R. M., Saper, C. B., Yanagisawa, M., and Elmquist, J. K. (2001) Differential expression of orexin receptors 1 and 2 in the rat brain J. Comp. Neurol. 435, 6 - 25
9. Trivedi, P., Yu, H., MacNeil, D. J., Van der Ploeg, L. H., and Guan, X. M. (1998) Distribution of orexin receptor mRNA in the rat brain FEBS Lett. 438, 71 - 75
10. Kukkonen, J. P., Holmqvist, T., Ammoun, S., and Akerman, K. E. (2002) Functions of the orexinergic/hypocretinergic system Am. J. Physiol.: Cell Physiol. 283, C1567 - 1591
11. Mahler, S. V., Moorman, D. E., Smith, R. J., James, M. H., and Aston-Jones, G. (2014) Motivational activation: A unifying hypothesis of orexin/hypocretin function Nat. Neurosci. 17, 1298 - 1303
12. Kukkonen, J. P. (2013) Physiology of the orexinergic/hypocretinergic system: A revisit in 2012 Am. J. Physiol.: Cell Physiol. 304, C2 - 32
13. Tsujino, N. and Sakurai, T. (2009) Orexin/hypocretin: a neuropeptide at the interface of sleep, energy homeostasis, and reward system Pharmacol. Rev. 61, 162 - 176
14. Mahler, S. V., Smith, R. J., Moorman, D. E., Sartor, G. C., and Aston-Jones, G. (2012) Multiple roles for orexin/hypocretin in addiction Prog. Brain Res. 198, 79 - 121
15. Harris, G. C., Wimmer, M., and Aston-Jones, G. (2005) A role for lateral hypothalamic orexin neurons in reward seeking Nature 437, 556 - 559
16. Boutrel, B., Kenny, P. J., Specio, S. E., Martin-Fardon, R., Markou, A., Koob, G. F., and de Lecea, L. (2005) Role for hypocretin in mediating stress-induced reinstatement of cocaine-seeking behavior Proc. Natl. Acad. Sci. U. S. A. 102, 19168 - 19173
17. Lawrence, A. J., Cowen, M. S., Yang, H. J., Chen, F., and Oldfield, B. (2006) The orexin system regulates alcohol-seeking in rats Br. J. Pharmacol. 148, 752 - 759
18. Richards, J. K., Simms, J. A., Steensland, P., Taha, S. A., Borgland, S. L., Bonci, A., and Bartlett, S. E. (2008) Inhibition of orexin-1/hypocretin-1 receptors inhibits yohimbine-induced reinstatement of ethanol and sucrose seeking in Long-Evans rats Psychopharmacology 199, 109 - 117
19. Roecker, A. J. and Coleman, P. J. (2008) Orexin receptor antagonists: medicinal chemistry and therapeutic potential Curr. Top Med. Chem. 8, 977 - 987
20. Boss, C., Brisbare-Roch, C., and Jenck, F. (2009) Biomedical application of orexin/hypocretin receptor ligands in neuroscience J. Med. Chem. 52, 891 - 903
21. Gatfield, J., Brisbare-Roch, C., Jenck, F., and Boss, C. (2010) Orexin receptor antagonists: A new concept in CNS disorders? ChemMedChem 5, 1197 - 1214
22. Kodadek, T. and Cai, D. (2010) Chemistry and biology of orexin signaling Mol. BioSyst. 6, 1366 - 1375
23. Scammell, T. E. and Winrow, C. J. (2011) Orexin receptors: Pharmacology and therapeutic opportunities Annu. Rev. Pharmacol. Toxicol. 51, 243 - 266
24. Mieda, M. and Sakurai, T. (2013) Orexin (hypocretin) receptor agonists and antagonists for treatment of sleep disorders. Rationale for development and current status CNS Drugs 27, 83 - 90
25. Winrow, C. J. and Renger, J. J. (2014) Discovery and development of orexin receptor antagonists as therapeutics for insomnia Br. J. Pharmacol. 171, 283 - 293
26. Yang, L. P. (2014) Suvorexant: First Global Approval Drugs 74, 1817 - 1822
27. Lebold, T. P., Bonaventure, P., and Shireman, B. T. (2013) Selective orexin receptor antagonists Bioorg. Med. Chem. Lett. 23, 4761 - 4769
28. Smart, D., Sabido-David, C., Brough, S. J., Jewitt, F., Johns, A., Porter, R. A., and Jerman, J. C. (2001) SB-334867-A: The first selective orexin-1 receptor antagonist Br. J. Pharmacol. 132, 1179 - 1182
29. Stasi, P. L. and Rovati, L. (2011) Spiro amino compounds suitable for the treatment of inter alia sleep disorders and drug addiction. WO2011006960, Rottapharm S.P.A.
30. Stasi, L. P., Artusi, R., Bovino, C., Buzzi, B., Canciani, L., Caselli, G., Colace, F., Garofalo, P., Giambuzzi, S., Larger, P., Letari, O., Mandelli, S., Perugini, L., Pucci, S., Salvi, M., and Toro, P. (2013) Discovery, synthesis, selectivity modulation and DMPK characterization of 5-azaspiro[2.4]heptanes as potent orexin receptor antagonists Bioorg. Med. Chem. Lett. 23, 2653 - 2658
31. Gozzi, A., Turrini, G., Piccoli, L., Massagrande, M., Amantini, D., Antolini, M., Martinelli, P., Cesari, N., Montanari, D., Tessari, M., Corsi, M., and Bifone, A. (2011) Functional magnetic resonance imaging reveals different neural substrates for the effects of orexin-1 and orexin-2 receptor antagonists PloS One 6, e16406
32. Steiner, M. A., Gatfield, J., Brisbare-Roch, C., Dietrich, H., Treiber, A., Jenck, F., and Boss, C. (2013) Discovery and Characterization of ACT-335827, an Orally Available, Brain Penetrant Orexin Receptor Type 1 Selective Antagonist ChemMedChem 8, 898 - 903
33. Jiang, R., Song, X., Bali, P., Smith, A., Bayona, C. R., Lin, L., Cameron, M. D., McDonald, P. H., Kenny, P. J., and Kamenecka, T. M. (2012) Disubstituted piperidines as potent orexin (hypocretin) receptor antagonists Bioorg. Med. Chem. Lett. 22, 3890 - 3894
34. Perrey, D. A., German, N. A., Gilmour, B. P., Li, J. X., Harris, D. L., Thomas, B. F., and Zhang, Y. (2013) Substituted tetrahydroisoquinolines as selective antagonists for the orexin 1 receptor J. Med. Chem. 56, 6901 - 6916
35. Perrey, D. A., Gilmour, B. P., Runyon, S. P., Thomas, B. F., and Zhang, Y. (2011) Diaryl urea analogues of SB-334867 as orexin-1 receptor antagonists Bioorg. Med. Chem. Lett. 21, 2980 - 2985
36. Perrey, D. A., Gilmour, B. P., Thomas, B. F., and Zhang, Y. (2014) Toward the Development of Bivalent Ligand Probes of Cannabinoid CB1 and Orexin OX1 Receptor Heterodimers ACS Med. Chem. Lett. 5, 634 - 638
37. Hirose, M., Egashira, S., Goto, Y., Hashihayata, T., Ohtake, N., Iwaasa, H., Hata, M., Fukami, T., Kanatani, A., and Yamada, K. (2003) N -Acyl 6,7-Dimethoxy-1,2,3,4-tetrahydroisoquinoline: The first orexin-2 receptor selective non-peptidic antagonist Bioorg. Med. Chem. Lett. 13, 4497 - 4499
38. Koberstein, R., Aissaoui, H., Bur, D., Clozel, M., Fischli, W., Jenck, F., Mueller, C., Nayler, O., Sifferlen, T., Treiber, A., and Weller, T. (2003) Tetrahydroisoquinolines as Orexin Receptor Antagonists: Strategies for Lead Optimization by Solution-Phase Chemistry Chimia 57, 270 - 275
39. Neubauer, D. N. (2010) Almorexant, a dual orexin receptor antagonist for the treatment of insomnia Curr. Opin. Invest. Drugs 11, 101 - 110
40. Borgland, S. L., Taha, S. A., Sarti, F., Fields, H. L., and Bonci, A. (2006) Orexin A in the VTA is critical for the induction of synaptic plasticity and behavioral sensitization to cocaine Neuron 49, 589 - 601
41. Thorn, D. A., Zhang, C., Zhang, Y., and Li, J. X. (2014) The trace amine associated receptor 1 agonist RO5263397 attenuates the induction of cocaine behavioral sensitization in rats Neurosci. Lett. 566, 67 - 71
42. Thorn, D. A., Jing, L., Qiu, Y., Gancarz-Kausch, A. M., Galuska, C. M., Dietz, D. M., Zhang, Y., and Li, J. X. (2014) Effects of the trace amine-associated receptor 1 agonist RO5263397 on abuse-related effects of cocaine in rats Neuropsychopharmacology 39, 2309 - 2316